Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2003 1
2004 2
2007 1
2010 1
2011 4
2012 5
2013 5
2014 4
2015 3
2016 3
2017 6
2018 5
2019 5
2020 10
2021 10
2022 11
2023 6
2024 11

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

82 results

Results by year

Filters applied: . Clear all
Page 1
Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study.
Bar-Or A, Wiendl H, Montalban X, Alvarez E, Davydovskaya M, Delgado SR, Evdoshenko EP, Giedraitiene N, Gross-Paju K, Haldre S, Herrman CE, Izquierdo G, Karelis G, Leutmezer F, Mares M, Meca-Lallana JE, Mickeviciene D, Nicholas J, Robertson DS, Sazonov DV, Sharlin K, Sundaram B, Totolyan N, Vachova M, Valis M, Bagger M, Häring DA, Ludwig I, Willi R, Zalesak M, Su W, Merschhemke M, Fox EJ. Bar-Or A, et al. Among authors: meca lallana je. Mult Scler. 2022 May;28(6):910-924. doi: 10.1177/13524585211044479. Epub 2021 Oct 4. Mult Scler. 2022. PMID: 34605319 Free PMC article. Clinical Trial.
Consensus statement of the Spanish Society of Neurology on the treatment of multiple sclerosis and holistic patient management in 2023.
Meca-Lallana JE, Martínez Yélamos S, Eichau S, Llaneza MÁ, Martín Martínez J, Peña Martínez J, Meca Lallana V, Alonso Torres AM, Moral Torres E, Río J, Calles C, Ares Luque A, Ramió-Torrentà L, Marzo Sola ME, Prieto JM, Martínez Ginés ML, Arroyo R, Otano Martínez MÁ, Brieva Ruiz L, Gómez Gutiérrez M, Rodríguez-Antigüedad Zarranz A, Sánchez-Seco VG, Costa-Frossard L, Hernández Pérez MÁ, Landete Pascual L, González Platas M, Oreja-Guevara C. Meca-Lallana JE, et al. Neurologia (Engl Ed). 2024 Mar;39(2):196-208. doi: 10.1016/j.nrleng.2024.01.003. Epub 2024 Jan 16. Neurologia (Engl Ed). 2024. PMID: 38237804 Free article.
Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial.
Foley JF, Defer G, Ryerson LZ, Cohen JA, Arnold DL, Butzkueven H, Cutter G, Giovannoni G, Killestein J, Wiendl H, Smirnakis K, Xiao S, Kong G, Kuhelj R, Campbell N; NOVA study investigators. Foley JF, et al. Lancet Neurol. 2022 Jul;21(7):608-619. doi: 10.1016/S1474-4422(22)00143-0. Epub 2022 Apr 25. Lancet Neurol. 2022. PMID: 35483387 Clinical Trial.
Effectiveness and Safety of Teriflunomide in Relapsing-Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study.
Meca-Lallana JE, Prieto González JM, Caminero Rodríguez AB, Olascoaga Urtaza J, Alonso AM, Durán Ferreras E, Espinosa R, Dotor J, Romera M, Ares Luque A, Pérez Ruiz D, Calles C, Hernández MA, Hervás García M, Mendoza Rodríguez A, Berdei Montero Y, Téllez N, Herrera Varó N, Sotoca J, Presas-Rodríguez S, Querol Gutierrez LA, Hervás Pujol M, Batlle Nadal J, Martín Ozaeta G, Gubieras Lillo L, Martínez Yélamos S, Ramió-Torrentà L, Mallada Frechin J, Belenguer Benavides A, Gascón-Giménez F, Casanova B, Landete Pascual L, Berenguer L, Navarro L, Gómez Gutierrez M, Durán C, Rodríguez Regal A, Álvarez E, García-Estévez DA, López Real AM, Llaneza González MA, Marzo Sola ME, Sánchez-Menoyo JL, Oterino A, Villaverde González R, Castillo-Triviño T, Álvarez de Arcaya A, Llarena C. Meca-Lallana JE, et al. Neurol Ther. 2023 Dec;12(6):2177-2193. doi: 10.1007/s40120-023-00557-7. Epub 2023 Oct 20. Neurol Ther. 2023. PMID: 37861931 Free PMC article.
[Biomarkers in multiple sclerosis].
Fernández Ó, Arroyo-González R, Rodríguez-Antigüedad A, García-Merino JA, Comabella M, Villar LM, Izquierdo G, Tintoré M, Oreja-Guevara C, Álvarez-Cermeño JC, Meca-Lallana JE, Prieto JM, Ramió-Torrentà L, Martínez-Yélamos S, Montalban X. Fernández Ó, et al. Among authors: meca lallana je. Rev Neurol. 2013 Apr 1;56(7):375-90. Rev Neurol. 2013. PMID: 23520007 Free article. Review. Spanish.
Investigating the 2023 MOGAD Criteria in Children and Adults With MOG-Antibody Positivity Within and Outside Attacks.
Fonseca E, Olivé-Cirera G, Martinez-Hernandez E, Guasp M, Naranjo L, Ruiz-García R, Caballero E, González-Álvarez V, Delgadillo V, Romeu G, Del-Prado-Sánchez C, Cabrera-Maqueda JM, Benito-León J, Iñiguez C, Garcia-Dominguez JM, Calles C, Cano A, Álvarez-Bravo G, González-Suárez I, Oreja-Guevara C, Ros M, Millan-Pascual J, Meca-Lallana JE, Borrega Canelo L, Martín-Martínez J, Palao M, Gracia J, Villaverde-González R, Llufriu S, Blanco Y, Saiz A, Dalmau J, Sepulveda M, Armangue T; Spanish MOGAD study group. Fonseca E, et al. Among authors: meca lallana je. Neurology. 2024 Sep 24;103(6):e209682. doi: 10.1212/WNL.0000000000209682. Epub 2024 Aug 27. Neurology. 2024. PMID: 39190859
[Oral treatments in multiple sclerosis].
Meca-Lallana JE, Hernández-Clares R, Carreón-Guarnizo E. Meca-Lallana JE, et al. Med Clin (Barc). 2014 Dec;143 Suppl 3:23-9. doi: 10.1016/S0025-7753(15)30006-3. Med Clin (Barc). 2014. PMID: 25732946 Review. Spanish.
12th Post-ECTRIMS Meeting: review of the novelties from the 2019 ECTRIMS Congress (II).
Fernández O, Aladro Y, Arroyo R, Brieva L, Calles-Hernández MC, Carrascal P, Comabella M, Costa-Frossard L, Eichau S, García-Merino JA, Ginestal R, González I, Izquierdo G, Martínez-Ginés ML, Meca-Lallana JE, Mendibe-Bilbao MM, Oterino A, Prieto JM, Río J, Ramió-Torrentà L, Romero-Pinel L, Téllez N, Rodríguez-Antigüedad A. Fernández O, et al. Among authors: meca lallana je. Rev Neurol. 2020 Jun 1;70(11):417-429. doi: 10.33588/rn.7011.2020122. Rev Neurol. 2020. PMID: 32436209 Free article. Review. English, Spanish.
Beyond lines of treatment: embracing early high-efficacy disease-modifying treatments for multiple sclerosis management.
Oreja-Guevara C, Martínez-Yélamos S, Eichau S, Llaneza MÁ, Martín-Martínez J, Peña-Martínez J, Meca-Lallana V, Alonso-Torres AM, Moral-Torres E, Río J, Calles C, Ares-Luque A, Ramió-Torrentà L, Marzo-Sola ME, Prieto JM, Martínez-Ginés ML, Arroyo R, Otano-Martínez MÁ, Brieva-Ruiz L, Gómez-Gutiérrez M, Rodríguez-Antigüedad A, Galán Sánchez-Seco V, Costa-Frossard L, Hernández-Pérez MÁ, Landete-Pascual L, González-Platas M, Meca-Lallana JE. Oreja-Guevara C, et al. Among authors: meca lallana je. Ther Adv Neurol Disord. 2024 Oct 16;17:17562864241284372. doi: 10.1177/17562864241284372. eCollection 2024. Ther Adv Neurol Disord. 2024. PMID: 39483817 Free PMC article. Review.
82 results